Dr. Reddys launches epilepsy drug in the US market

Dr. Reddy


Drug maker Dr. Reddys Laboratories Ltd said on Wednesday it launched lamotrigine extended-release tablets in the US market following approval by the Food and Drug Administration on 25 June.
Lamotrigine is a generic version of GlaxoSmithKline Plc.s lamictal XR used in the treatment of epilepsy.
According to US-based healthcare information service provider IMS Health, the lamictal XR brand and its generic had combined US sales of around $300.5 million for the 12 months ended April.
Dr. Reddys lamotrigine tablets will be available in 25mg, 50mg, 100mg, 200mg, and 300mg dosages.

Follow and connect with us on Facebook, Twitter, LinkedIn, Elets video

Eletsonline News

Follow us on

Most Popular

200000+ Subscribers read it every day.
Subscribe Newsletter
To Top